|Description||A-836339 is a synthetic and potent cannabinoid receptor full agonist. It displays a higher affinity for the peripheral CB2 receptor with Ki value of 0.64 nM over the central CB1 receptor with Ki of 270 nM in both human and rat in radioligand binding assays. It also displays analgesic, anti-inflammatory, and anti-hyperalgesic effects in mice at low doses. It exhibits a profile devoid of significant affinity at other G-protein-coupled receptors and ion channels. It has also demonstrated efficacies in the chronic constrain injury (CCI) model of neuropathic pain, skin incision, and capsaicin-induced secondary mechanical hyperalgesia models. It is intended for forensic and research applications. It was suggested to be for human consumption. It was developed by Abbott Laboratories.|
|Appearance||Light yellow to yellow Solid|
|Synonyms||N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide;CyclopropanecarboxaMide, N-[3-(2-Methoxyethyl)-4,5-diMethyl-2(3H)-thiazolylidene]-2,2,3,3-tetraMethyl-, [N(Z)]-;1-(Tetrahydropyran-4-ylMethyl)-1H-indol-3-yl]-(2,2,3,5-tetraMethylcyclopropyl)Methanone|
|Solubility||DMSO: ≥ 12 mg/mL|
|Application||A-836339 displays analgesic, anti-inflammatory, and anti-hyperalgesic effects. It was suggested to be for human consumption.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||388.4±44.0 °C | Condition: Press: 760 Torr|
|Density||1.14±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||A-836339 was developed by Abbott Laboratories.|
UCM 707 is a potent endocannabinoid transport inhibitor (IC50 = 0.8 and 30 μM for inhibition of the anandamide transporter and FAAH, respectively). UCM 707 pote...
PSNCBAM-1 is an allosteric, non-competitive antagonist of CB-1 (IC50= 45 and 209 nM) with hypophagic effects in vivo, potentially an anti-obesity agents.
AM-1220 is a selective cannabinoid receptor CB1 agonist , with about 19x selectivity for CB1 over the related CB2 receptor originated by Sterling Winthrop. In O...
(R)-(+)-SLV 319 is a less active enantiomer of SLV 319, which is a central cannabinoid (CB1) receptor antagonist. SLV 319 has the potential to treat neuroinflam...
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
Iodopravadoline, also known as AM630, is an inverse agonist at the human cannabinoid CB1 receptor. Iodopravadoline has been found to attenuate the ability of a ...
Rimonabant Hydrochloride, used as a tool to investigate CB receptor properties, it is a selective antagonist of cannabinoid CB1 receptor (Ki = 1.98 nM) and inve...
CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.